Skin topical formulation composition containing cross-linked polyglutamic acid

Abstract

The present invention provides a topical skin preparation composition that uses cross-linked polyglutamic acid or a salt thereof and has a unique sherbet-like texture and high moisture content. [Solution] The topical skin composition of the present invention is an oil-in-water topical skin composition comprising an aqueous phase and an oil phase, wherein the aqueous phase comprises crosslinked polyglutamic acid or a salt thereof, and the oil phase comprises emulsion particles. A topical skin composition according to one embodiment of the present invention provides less stickiness and smooth application during application, and can help maintain skin moisture content after application.

Description

Technical Field

[0001] The present invention relates to a composition for external use on the skin that uses cross-linked polyglutamic acid or a salt thereof and provides a unique texture like sherbet and a high water content.

Background Art

[0002] In products of the type used by applying to the skin such as cosmetics, the feeling of use is one of the elements that decisively affects consumer satisfaction together with the functionality or efficacy of the product. Along with this, products showing various feelings of use have been developed. As a typical unique feeling of use of cosmetics, there is a feeling of water bouncing or a feeling of moisture, but such a feeling of use has a limitation that it can be provided only when the discontinuous phase is an aqueous phase as in an oil-in-water type (W / O, Water in Oil or W / S, Water in Silicon oil) emulsion.

[0003] However, since the continuous phase of this dosage form is oil or silicone oil, a strong initial "shine" may be felt. In addition, the oil component of the continuous phase may remain on the skin and give a feeling of only bouncing the water component, and there are drawbacks such as the oil component or silicone oil component of the continuous phase irritating the skin or residues remaining and making washing difficult.

[0004] Therefore, there is a practical need to develop a composition for external use on the skin that provides a high water content while providing a unique feeling of use that is not an oil-in-water type emulsion.

Prior Art Documents

Patent Documents

[0005]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0006] The present invention aims to provide a topical skin preparation composition that uses cross-linked polyglutamic acid or a salt thereof and has a unique sherbet-like texture and high moisture content. [Means for solving the problem]

[0007] According to the first aspect of the present invention, The present invention provides an oil-in-water (Oil in Water) topical skin preparation composition comprising an aqueous phase and an oil phase, wherein the aqueous phase comprises crosslinked polyglutamic acid or a salt thereof, and the oil phase comprises emulsified particles.

[0008] In one embodiment of the present invention, the particle size of the crosslinked polyglutamic acid or its salt may be 20 μm to 300 μm.

[0009] In one embodiment of the present invention, the content of the crosslinked polyglutamic acid or its salt may be 0.001% to 10% by weight, based on 100% by weight of the total composition.

[0010] In one embodiment of the present invention, the crosslinked polyglutamic acid or salt particles may be non-sphere type particles.

[0011] In one embodiment of the present invention, the composition may have a sherbet-like texture.

[0012] In one embodiment of the present invention, the composition may be used for skin moisturizing.

[0013] In one embodiment of the present invention, the composition may be a cosmetic composition.

[0014] According to a second aspect of the present invention, The present invention provides a method for producing the aforementioned topical skin composition, comprising: (1) irradiating an aqueous solution of polyglutamic acid or a salt thereof with an electron beam at an irradiation dose of 50 kGy to 300 kGy to form crosslinks between polyglutamic acids; and (2) adjusting the size of the crosslinked polyglutamic acid particles to 20 μm to 300 μm.

[0015] In one embodiment of the present invention, the weight-average molecular weight of the polyglutamic acid or its salt in (1) above may be 10,000 Da to 80,000 Da. [Effects of the Invention]

[0016] A topical skin preparation composition according to one embodiment of the present invention contains crosslinked polyglutamic acid or a salt thereof, has a unique sherbet-like texture and high water content, is less sticky, provides smooth application, and helps maintain skin moisture levels after application. [Brief explanation of the drawing]

[0017] [Figure 1] This diagram illustrates the reaction mechanism by which polyglutamic acid is crosslinked by electron beam irradiation. [Figure 2] This graph shows the particle size distribution of Example 1. [Figure 3] This is an optical microscope image (40x magnification) showing the particle size of Example 1. [Figure 4] This is an optical microscope image (200x magnification) showing the particle size of Example 1. [Figure 5] This is a photograph showing the external appearance of Example 1. [Figure 6] This is a photograph showing the appearance of Comparative Example 2. [Figure 7] This graph shows the results of measuring the amount of moisture over time after application in Example 1, Comparative Examples 1 and 2. [Figure 8] This graph shows the results of evaluating the applicability of Comparative Example 3. [Figure 9] This figure shows the results of evaluating the applicability of Example 1 in graph form.

Embodiments for Carrying out the Invention

[0018] The embodiments provided by the present invention can all be achieved by the following description. It should be understood that the following description describes the preferred embodiments of the present invention, and it should be understood that the present invention is not necessarily limited thereto.

[0019] Regarding the physical properties described in this specification, when the measurement conditions and methods are not specifically described, the physical properties are measured according to the measurement conditions and methods generally used by ordinary technicians in the relevant technical field.

[0020] Throughout this specification, when a certain part states that a certain component "comprises", unless otherwise stated to the contrary, it does not exclude other components, but means that other components can be further included.

[0021] Throughout this specification, "%", unless otherwise explicitly indicated, means weight %.

[0022] Topical skin composition According to one aspect of the present invention, the present invention provides an oil-in-water topical skin composition comprising an aqueous phase and an oil phase, wherein the aqueous phase contains polyglutamic acid crosslinked thereto or a salt thereof, and the oil phase contains emulsified particles.

[0023] As used herein, "topical skin composition" means a composition in a dosage form to be applied externally to the skin. The topical skin composition can be directly applied by hand or using various application means such as a spatula, and can include various dosage forms of cosmetics, pharmaceuticals, quasi-drugs, etc.

[0024] According to one embodiment of the present invention, the polyglutamic acid (PGA) may be a water-soluble polymer composed of glutamic acid linked by peptide bonds. Although polyglutamic acid has a much better water-retention capacity than hyaluronic acid, it had the drawback of being difficult to use as a cosmetic ingredient due to its sticky feel. However, by crosslinking polyglutamic acid, the stickiness can be reduced and a silky feel can be provided, significantly improving this drawback. Furthermore, crosslinked polyglutamic acid can retain more water than uncrosslinked polyglutamic acid, its stability is enhanced, and its resistance to degradation can also be strengthened. In this specification, "silky feel" means a feel in which the composition spreads softly and smoothly when applied to the skin, giving a soft, silky sensation. Compositions having a silky feel penetrate lightly without stickiness, providing moisture, and can adhere softly to the skin without leaving any residue.

[0025] According to one embodiment of the present invention, the polyglutamic acid may exist in salt form, and the salt is not particularly limited, but may be an acid addition salt, a base addition salt, or an amino acid salt. For example, the salt may be an inorganic acid such as hydrochloride, hydrobromide, sulfate, hydroiodide, nitrate, or phosphate; an organic acid such as citrate, oxalate, acetate, formate, propionate, benzoate, trifluoroacetate, maleate, stanate, methanesulfonate, benzenesulfonate, or p-toluenesulfonate; an inorganic base salt such as sodium salt, potassium salt, calcium salt, magnesium salt, copper salt, zinc salt, aluminum salt, or ammonium salt; an organic base salt such as triethylammonium salt, triethanolammonium salt, pyridinium salt, or diisopropylammonium salt; or an amino acid salt such as lysine salt, arginine salt, histidine salt, aspartate, or glutamate. According to one embodiment of the present invention, the salt may be a sodium polyglutamate salt, a potassium polyglutamate salt, a polyglutamate acetate salt, or an ammonium polyglutamate salt.

[0026] According to one embodiment of the present invention, the crosslinking of the polyglutamic acid or its salt can be carried out by an electron beam, but the crosslinking method is not particularly limited.

[0027] According to one embodiment of the present invention, the topical skin preparation composition may have a sherbet-like texture and appearance. In this case, "sherbet" can mean a state in which, when the composition is applied by pressing it onto a glass plate and its appearance is checked, it has a granular texture while having a light, soft, and fluffy physical property similar to foam (see Figure 5). According to one embodiment of the present invention, the composition can be spread softly and melt like sherbet when used, and the user can continuously feel the moisture sensation when the crosslinked polyglutamic acid or salt particles burst and the oil sensation when the emulsion particles burst.

[0028] According to one embodiment of the present invention, the composition may contain particles of crosslinked polyglutamic acid or a salt thereof having a particle size distribution in the aqueous phase where D(0.5) is 20 μm to 300 μm. In this case, the particle size distribution is expressed as a percentage of the ratio of a group of particles within a certain particle size range to the total group of particles, and this is illustrated in a particle size distribution curve. D(0.5) is also called D50, D(V, 0.5), or median particle size. D(0.5) represents the size of particles distributed in the middle 50% of the particle size distribution diagram and appears as a peak on the distribution diagram. According to one embodiment of the present invention, 20 μm to 300 μm can represent the size of at least 50%, 60%, 70%, 80%, or 90% of the particles contained in the composition. That is, the range may be values ​​of D(0.5), D(0.6), D(0.7), D(0.8), or D(0.9). According to one embodiment of the present invention, the particle size distribution can be measured using a Malvern Panalytical Mastersizer 2000, which is a Rayseel diffraction particle size analyzer. However, the method or type of particle size analyzer is not limited as long as it is capable of measuring particle size distribution.

[0029] According to one embodiment of the present invention, the particles of the crosslinked polyglutamic acid or its salt may have a particle size distribution in which D(0.5) is 20 μm to 300 μm, 40 μm to 250 μm, 60 μm to 200 μm, 20 μm or more, 40 μm or more, 60 μm or more, 80 μm or more, 100 μm or more, 120 μm or more, 300 μm or less, 280 μm or less, 260 μm or less, 240 μm or less, 220 μm or less, or 200 μm or less. In the particle size distribution, if the D(0.5) value is less than 20 μm, the silky feel may be poor, and the use of an excessive amount of thickener may result in a sticky residue. If the D(0.5) value of the gel particles exceeds 300 μm, the particles are excessively large, preventing the sherbet-like soft texture from appearing. This can lead to a feeling of foreign matter in the product, reducing the user experience, and potentially impairing the long-term stability of the dosage form.

[0030] According to one embodiment of the present invention, the crosslinked polyglutamic acid or salt particles may be non-sphere type particles. These "non-sphere type particles" may deviate from conventional spherical shapes and exhibit diverse and irregular geometric structures, and unlike spherical particles having isotropic and uniform curvature, they may have complex structures such as elongated, flattened, rod-shaped, disc-shaped, ellipsoidal, fibrous, or other asymmetrical shapes. Non-sphere type crosslinked polyglutamic acid or salt particles according to one embodiment of the present invention can be structurally stronger than other polyglutamic acids having spherical particles, can improve the mechanical properties of the composition, and can provide a unique feel such as a silky feel. They can also have a larger surface area relative to their volume and can provide a high moisture content.

[0031] According to one embodiment of the present invention, the crosslinked polyglutamic acid or a salt thereof may be present in an amount of 0.001% to 10% by weight per 100% by weight of the total composition. Specifically, it may be present in an amount of 0.001% to 10% by weight, 0.01% to 7% by weight, 0.1% to 4% by weight, or more than 0.001% by weight, more than 0.01% by weight, more than 0.1% by weight, more than 0.2% by weight, more than 0.3% by weight, more than 0.4% by weight, or less than 10% by weight, less than 9% by weight, less than 8% by weight, less than 7% by weight, less than 6% by weight, or less than 5% by weight. If the amount falls outside the above range, the characteristic appearance and texture of sherbet may not be achieved.

[0032] According to one embodiment of the present invention, the type of oil contained in the emulsified particles is not limited as long as it is an oil commonly used in the art, and may be an ester-based oil, a hydrocarbon-based oil, a naturally derived oil, a silicone-based oil, etc. Specifically, the oil contains polydecene, hydrogenated polydecene, polybutene, hydrogenated polyisobutene, dicaprylyl carbonate, diisostearylmalate, butylene glycol dicaprylate / dicaprate, cetyl 2-ethyl hexanoate, triethylhexanoin, caprylic / capric triglyceride, dicetearyl dimer dilinoleate, diisostearyl malate, and hexyl laurate. (laurate), pentaerythrityl tetraethylhexanoate, pentaerythrityl tetraisostearate, octyldodecyl stearoyl stearate, cyclopentasiloxane, cyclohexasiloxane, dimethicone, methyl trimethicone, cyclomethicone, phenyl trimethicone, squalane, tamanu oil, macadamia nut oilIt may also be one or more oils selected from the group consisting of sunflower seed oil, olive oil, evening primrose oil, argan oil, apricot oil, sesame oil, orange oil, rosewood oil, bergamot oil, camellia oil, tea tree oil, and jojoba oil.

[0033] According to one embodiment of the present invention, the use of the skin topical preparation composition may be for skin moisturizing.

[0034] According to one embodiment of the present invention, the topical skin preparation composition may be a cosmetic composition. The cosmetic composition may contain a cosmetically or dermatologically acceptable medium or base. It may be provided in all dosage forms suitable for topical application, such as solutions, gels, anhydrous preparations, emulsions obtained by dispersing an oil phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranulocytes, or ionic (liposomes) and nonionic vesicle dispersants, creams, skin lotions, milky lotions, ointments, etc. These compositions can be manufactured according to conventional methods of the art.

[0035] The aforementioned cosmetic composition is not particularly limited in its dosage form and can be formulated as a skincare composition, a makeup composition, a body, haircare, or cleansing composition, etc.

[0036] According to one embodiment of the present invention, the cosmetic composition can be formulated into cosmetics such as ampoules, creams, softening lotions, astringent lotions, nourishing lotions, nourishing creams, massage creams, essences, eye creams, eye essences, cleansing creams, cleansing foams, cleansing waters, cleansing tissues containing the cosmetic composition, packs, body lotions, body creams, body oils, and body essences. According to one embodiment of the present invention, the cosmetic composition can be formulated into cosmetics such as makeup primers, makeup bases, foundations, concealers, lipsticks, lip glosses, lip balms, powders, lip liners, eyeliners, mascaras, eyebrow products, eyeshadows, blushes, cushion foundations, or UV protection agents. According to one embodiment of the present invention, the cosmetic composition can be formulated into a body wash, facial wash, hand wash, hair shampoo, hair rinse, hair conditioner, hair treatment, hair tonic, scalp treatment, scalp and hair treatment, hair lotion, hair cream, hair nourishing lotion, or general ointment.

[0037] According to one embodiment of the present invention, when the dosage form is a paste, cream, or gel, animal fibers, plant fibers, wax, paraffin, starch, tracant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as the carrier component. According to one embodiment of the present invention, when the dosage form is a solution or emulsion, a solvent, solvating agent, or emulsifying agent may be used as the carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan may be used. According to one embodiment of the present invention, when the dosage form is a suspension, liquid diluents such as water, ethanol, or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum methhydroxyl, bentonite, agar, or tracant may be used as the carrier component. According to one embodiment of the present invention, when the dosage form is a surfactant-containing cleanser, the carrier component may be an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, aliphatic alcohol monoester, sulfosuccinate, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamide betaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolenic acid derivative, or ethoxylated glycerol fatty acid ester.

[0038] According to one embodiment of the present invention, the cosmetic composition may further contain functional additives and components commonly found in cosmetic compositions. The functional additives may include components selected from the group consisting of water-soluble vitamins, fat-soluble vitamins, high molecular weight peptides, high molecular weight polysaccharides, sphingolipids, and seaweed extracts. Other components that may be included include oils and fats, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, UV absorbers, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, dyes, fragrances, blood circulation promoters, cooling agents, antiperspirants, purified water, and the like.

[0039] According to one embodiment of the present invention, the composition may be a pharmaceutical composition. The pharmaceutical composition can be formulated into a dosage form for parenteral administration in a semi-solid or liquid form by adding a commercially available inorganic or organic carrier to the active ingredient used in one embodiment of the present invention. The composition according to one embodiment of the present invention can be easily formulated into a dosage form of the active ingredient by carrying out conventional methods widely known in the art, in which surfactants, excipients, colorants, spices, preservatives, stabilizers, buffers, suspending agents, and other commercially available auxiliary agents may be used as appropriate. The dosage of the active ingredient in the pharmaceutical composition according to one embodiment of the present invention will vary depending on the age, sex, weight, pathological condition and its severity, route of administration, or judgment of the prescriber. Determining an appropriate dosage based on such factors is within the level of those skilled in the art, and the daily dosage may be, for example, 0.1 mg / kg / day to 100 mg / kg / day, more specifically 5 mg / kg / day to 50 mg / kg / day, but is not limited thereto.

[0040] Method for producing topical skin preparations According to one aspect of the present invention, the present invention provides a method for producing the aforementioned topical skin preparation composition. The method for producing the topical skin preparation composition according to one embodiment of the present invention includes (1) irradiating an aqueous solution of polyglutamic acid or a salt thereof with an electron beam at an irradiation dose of 50 kGy to 300 kGy to form crosslinks between polyglutamic acids; and (2) adjusting the size of the crosslinked polyglutamic acid particles to 20 μm to 300 μm.

[0041] As the specific details of polyglutamic acid or its salts in the method for producing the aforementioned topical skin composition are as described above, further details will be omitted below.

[0042] In step (1) above, an aqueous solution of polyglutamic acid or a salt thereof is irradiated with an electron beam at an irradiation dose of 50 kGy to 300 kGy to form crosslinks between polyglutamic acid molecules.

[0043] According to one embodiment of the present invention, the formation of crosslinks between polyglutamic acids can be carried out chemically with a crosslinking agent or by irradiation with an electron beam, but is not limited to these methods as long as it is a method that can form crosslinks.

[0044] According to one embodiment of the present invention, when crosslinking between polyglutamic acids is performed by irradiation with an electron beam, the irradiation dose of the electron beam may be 50 kGy to 300 kGy. Specifically, it may be 50 kGy to 300 kGy, 80 kGy to 250 kGy, 110 kGy to 200 kGy, 50 kGy or more, 60 kGy or more, 70 kGy or more, 80 kGy or more, 90 kGy or more, and 300 kGy or less, 270 kGy or less, 240 kGy or less, 210 kGy or less, or 180 kGy or less. By satisfying the above range, crosslinking between polyglutamic acids proceeds sufficiently, the composition can have a unique sherbet-like texture, and may have excellent coatability.

[0045] According to one embodiment of the present invention, the weight-average molecular weight of the polyglutamic acid or its salt may vary depending on the length of the chain, and may be between 10,000 Da and 80,000 Da. Specifically, the weight-average molecular weight of the polyglutamic acid or its salt may be between 10,000 Da and 80,000 Da, 20,000 Da and 70,000 Da, 30,000 Da and 60,000 Da, or 10,000 Da or more, 15,000 Da or more, 20,000 Da or more, 25,000 Da or more, 30,000 Da or more, or 80,000 Da or less, 75,000 Da or less, 70,000 Da or less, 65,000 Da or less, or 60,000 Da or less. By satisfying the above range, the composition can contain sufficient moisture and exhibit a unique appearance and texture similar to sherbet.

[0046] In step (2) above, the cross-linked polyglutamic acid particles are adjusted to a size of 20 μm to 300 μm.

[0047] According to one embodiment of the present invention, the method is not limited as long as it can produce particles within the aforementioned size range. The crosslinked polyglutamic acid can be produced by passing it through a mesh and grinding it, or by stirring it with a homo mixer to adjust the particle size.

[0048] According to one embodiment of the present invention, when the particle size adjustment is performed using a homomixer, the particle size can be adjusted by stirring the crosslinked polyglutamic acid at 5,000 rpm to 15,000 rpm for 1 to 10 minutes.

[0049] According to one embodiment of the present invention, the topical skin preparation composition can be produced by adding and mixing the crosslinked polyglutamic acid to an oil-in-water composition produced according to a conventional method for producing oil-in-water compositions in the industry. According to one embodiment of the present invention, the conventional method for producing the oil-in-water composition may be, but is not limited to, a method in which an aqueous phase containing aqueous components and an oil phase containing oily components are produced, and then the oil phase is added to the aqueous phase and stirred.

[0050] The following are preferred embodiments to aid in understanding the present invention, but these embodiments are provided only to facilitate understanding the present invention and are not limited thereto.

[0051] Manufacturing example Examples 1 and 4 (Cream Type) Examples 1 and 4, having the compositions shown in Table 1 below, were prepared by the following method.

[0052] First, polyglutamic acid (manufacturer: Hyundai Bioland), which had been crosslinked by 140 kGy electron beam irradiation, was stirred at 9,000 rpm for 3 minutes using a homomixer (manufacturer: Primix, product name: Mark2 2.5) to produce particles in which D(0.5) was located between 20 μm and 300 μm in the particle size distribution.

[0053] Then, the crosslinked polyglutamic acid was added to and mixed with the oil-in-water composition prepared according to the composition shown in Table 1 below to produce Examples 1 and 4. Specifically, dicaprylyl ether, squalane, and C14-22 alcohol * C12-20 alkyl glucoside were added to a reactor in the composition ratios shown in Table 1 using an AGI TATOR (2L) and heated to 75°C to completely dissolve the oil phase. Separately, sodium metaphosphate and propanediol were added to distilled water in the composition ratios shown in Table 1 and heated to 75°C to completely dissolve the aqueous phase. The oil phase was slowly added to the aqueous phase while stirring at 9000 rpm for 3 minutes using a Primix (Mark2 2.5). The mixture was slowly mixed with polyacrylate-13 at 9000 rpm for 2 minutes, then the crosslinked polyglutamic acid was added and mixed further at 9000 rpm for 2 minutes to produce a topical skin preparation composition.

[0054] Example 2 (Toner Type) Example 2, having the composition shown in Table 1 below, was prepared by the following method.

[0055] Sodium metaphosphate and propanediol were added to distilled water in the composition ratios shown in Table 1 in a reactor, and the aqueous phase was completely dissolved at room temperature. Crosslinked polyglutamic acid, produced by the same method as in Example 1, was added to the aqueous phase, and the mixture was stirred at 9000 rpm for 2 minutes to produce a topical skin preparation composition.

[0056] Example 3 (Emulsion Type) Example 3, having the composition shown in Table 1 below, was prepared by the following method.

[0057] Dicaprylyl ether, squalane, and C14-22 alcohol * C12-20 alkyl glucoside were added to a reactor in the composition ratios shown in Table 1 using an AGI TATOR (2L) and heated to 75°C until the oil phase was completely dissolved. Separately, sodium metaphosphate and propanediol were added to distilled water in the composition ratios shown in Table 1 and heated to 75°C until the aqueous phase was completely dissolved. The oil phase was slowly added to the aqueous phase while stirring at 9000 rpm for 3 minutes using a Primix (Mark2 2.5). Polyacrylate-13 was slowly added to the mixture while stirring at 9000 rpm for 2 minutes. Then, crosslinked polyglutamic acid, prepared in the same manner as in Example 1, was added and stirred further at 9000 rpm for 2 minutes to produce a topical skin preparation composition.

[0058] Comparative Example 1 A topical skin preparation composition was prepared in the same manner as in Example 1, except that instead of cross-linked polyglutamic acid with D(0.5) between 20 μm and 300 μm, cross-linked polyglutamic acid with D(0.5) exceeding 300 μm was added without stirring the cross-linked polyglutamic acid using a homomixer.

[0059] Comparative Example 2 A topical skin preparation composition was prepared in the same manner as in Example 1, except that uncrosslinked polyglutamic acid was used instead of crosslinked polyglutamic acid with D(0.5) of 20 μm to 300 μm.

[0060] Comparative Example 3 A topical skin preparation composition was prepared in the same manner as in Example 1, except that cross-linked polyglutamic acid with D(0.5) of 20 μm to 300 μm was not added, according to the composition in Table 1 below.

[0061] [Table 1]

[0062] Experimental example Experimental Example 1 (pH and Viscosity Evaluation) The pH, hardness, and viscosity of the topical skin preparation compositions of Examples 1-4 and Comparative Examples 1-3 were measured. Viscosity was measured using a rotary viscosity meter (RVDV2T, BROOKFIELD), hardness was measured using a hardness meter (CR-100, Sun Scientific), and pH was measured using a pH meter (S-220 Mettler, Mettler Toledo). All measurements were taken at room temperature (26°C). The measurement results are summarized in Table 2 below.

[0063] [Table 2]

[0064] Cosmetics can be distributed if the pH is measured between 3.0 and 9.0, and all of Examples 1-4 and Comparative Examples 1-3 were measured to satisfy this range. The hardness of Example 1, Comparative Example 1, and Comparative Example 3 was measured at similar levels. Furthermore, the viscosity of Examples 2 and 3 was measured to be lower than that of Comparative Example 2.

[0065] Experimental Example 2 (Evaluation of particle size of topical skin preparation compositions) The particle size distribution of the topical skin preparation composition of Example 1 was measured using a Malvern Panalytical Mastersizer 2000, and the results are shown in Figure 2. The particle size of the topical skin preparation composition of Example 1 was then measured using an optical microscope (manufacturer: Nikon Instruments Korea Co., Ltd., model name: Microscope 80i, ×40x and ×200x), and the results are shown in Figures 3 and 4, respectively.

[0066] According to Figure 2, Example 1 shows an emulsion particle peak (D(0.5)) in the range of 20 μm to 300 μm. According to Figures 3 and 4, Example 1 was found to have a particle size of approximately 20 μm to 300 μm and a non-sphere type particle shape.

[0067] Experimental Example 3 (Evaluation of the appearance and feel of topical skin preparation compositions) The topical skin preparation compositions of Example 1 and Comparative Example 2 were thinly applied to a glass plate by pressing them against it, and then photographed, as shown in Figures 5 and 6. Then, approximately 0.3 ml each of the topical skin preparation compositions of Example 1 and Comparative Examples 1-3 were taken, placed on the back of the hand, and applied for about 20 seconds under rolling conditions of 2 times per second. The overall feeling of use on the back of the hand was then confirmed.

[0068] As shown in Figures 5 and 6, Example 1, which contained crosslinked polyglutamic acid, exhibited a unique appearance with a sherbet-like texture, while Comparative Example 2, which contained uncrosslinked polyglutamic acid, exhibited the appearance of a simple emulsion.

[0069] Example 1 exhibited a silky feel, while Comparative Example 1 showed poor stability over time and a strong foreign body sensation similar to a scrub agent. Comparative Example 2 had a strong sticky feel and lower viscosity at the same thickening agent content. Comparative Example 3 also lacked flexibility upon application, and the increased amount of thickening agent used to achieve a viscosity similar to Example 1 resulted in an increased sticky residue.

[0070] Experimental Example 4 (Evaluation of the moisture content of cross-linked gels for topical skin preparations) Skin moisture content was measured using the topical skin preparation compositions of Example 1, Comparative Examples 1 and 2. Specifically, skin moisture content was measured using a Corneometer CM825 WL immediately before application of the topical skin preparation composition to the forearm of an adult male, 3 hours after application, and 6 hours after application. The results are shown in Figure 7.

[0071] As shown in Figure 7, the composition of Example 1 maintains a generally higher moisture content compared to Comparative Examples 1 and 2.

[0072] Experimental Example 5 (Evaluation of the applicability of cross-linked gels for topical skin preparations) The applicability of the topical skin preparation compositions of Example 1 and Comparative Example 3 was measured. After applying equal amounts of each composition to artificial leather, the V value was measured using a device that quantifies frictional force and tackiness using a Piezosensor friction coefficient (measuring device: UTPSM (Universal Tactile Pressure Sensor Measurement) System-based development device, trademark name: Sensanoid, TerraLeader Co., Ltd., Korea). Specifically, with the sample applied to the artificial leather, a fingerprint pattern PDMS sensor was applied vertically with a constant pressure (0.02 N). Subsequently, it was moved horizontally at a speed of 7 mm / s, and the frictional force was continuously measured in units of 1 / 100 seconds. The results are shown in Figures 8 and 9. A lower V value indicates lower resistance of the contents and superior applicability.

[0073] According to Figures 8 and 9, in Example 1, the V value was measured to be less than 0.4 throughout the entire range, indicating that the contents were given a rolling sensation that allowed for smooth application to the skin. In Comparative Example 3, there were sections where the V value exceeded 0.4, indicating that it had higher resistance and poorer application compared to Example 1.

[0074] From the results described above, it can be seen that the topical skin preparation composition of the present invention has a silky feel and excellent applicability, and also ensures excellent moisture retention.

[0075] Any simple modifications or changes to the present invention fall within the scope of the present invention, and the specific scope of protection of the present invention will be clarified by the appended claims.

Claims

1. An oil-in-water (Oil in Water) skin topical preparation composition comprising an aqueous phase and an oil phase, The aqueous phase comprises crosslinked polyglutamic acid or a salt thereof. The oil phase is an oil-in-water type topical skin preparation composition containing emulsified particles.

2. The topical skin preparation composition according to claim 1, wherein the particle size of the crosslinked polyglutamic acid or its salt is 20 μm to 300 μm.

3. The skin topical preparation composition according to claim 1, wherein the content of the crosslinked polyglutamic acid or a salt thereof is 0.001% by weight to 10% by weight, based on 100% by weight of the total composition.

4. The topical skin preparation composition according to claim 1, wherein the crosslinked polyglutamic acid or salt particles are non-sphere type particles.

5. The composition is a topical skin preparation composition according to claim 1, having the texture of sherbet.

6. The composition for external use on the skin according to claim 1, wherein the use of the composition is for moisturizing the skin.

7. The composition is a cosmetic composition, as described in claim 1.

8. (1) A step of irradiating an aqueous solution of polyglutamic acid or a salt thereof with an electron beam at an irradiation dose of 50 kGy to 300 kGy to form crosslinks between polyglutamic acids; and (2) A method for producing a topical skin composition according to claim 1, comprising the step of adjusting the crosslinked polyglutamic acid particles to 20 μm to 300 μm.

9. A method for producing a topical skin preparation composition according to claim 8, wherein the weight-average molecular weight of the polyglutamic acid or salt of (1) is 10,000 Da to 80,000 Da.

Images